“`html
09/01/2025 – 05:00 PM
– Conference Call and Webcast to be held Tuesday, September 2, 2025, at 8:00 a.m. ET –
WALTHAM, Mass. – Upstream Bio (NASDAQ:UPB) is making waves with its lead therapeutic, verekitug, and investors are keen to hear the latest. The clinical-stage biotech firm, focused on innovative treatments for inflammatory diseases, particularly severe respiratory conditions, announced it will unveil top-line data from its Phase 2 VIBRANT trial on Tuesday, September 2, 2025. The news is expected to shed light on the potential of verekitug, a monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), a key driver of inflammatory responses.
The VIBRANT trial (NCT06164704), a global, randomized, placebo-controlled study, is evaluating verekitug’s efficacy and safety in adult patients diagnosed with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Participants in the trial received either 100 mg of verekitug or a placebo via subcutaneous injection every 12 weeks over a 24-week period. The study’s primary endpoint is the change in endoscopic nasal polyp score (NPS) observed at Week 24, a critical measure for assessing the drug’s impact. Analysts are watching this data closely to gauge the treatment’s efficacy and potential market impact.
Upstream Bio isn’t just another biotech startup; it’s strategically positioned itself by targeting TSLP, a clinically validated cytokine sitting “upstream” of multiple inflammatory signaling cascades. This unique approach allows verekitug to potentially address a broader range of immune-mediated diseases. Positive results from the VIBRANT trial could significantly boost UPB’s stock and accelerate the development of verekitug across multiple indications.
Conference Call and Webcast
Investors and analysts can tune into Upstream Bio’s conference call and webcast on Tuesday, September 2, 2025, at 8:00 a.m. ET for a detailed discussion of the VIBRANT trial results.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care.
FAQ
When will Upstream Bio (UPB) report Phase 2 VIBRANT trial results?
Upstream Bio will report the top-line data from the Phase 2 VIBRANT trial on Tuesday, September 2, 2025, at 8:00 a.m. ET via conference call and webcast.
What is the primary endpoint of Upstream Bio’s Phase 2 VIBRANT trial?
The primary endpoint of the VIBRANT trial is the change in endoscopic nasal polyp score (NPS) at Week 24.
How is verekitug administered in the Upstream Bio VIBRANT trial?
In the VIBRANT trial, participants received 100 mg of verekitug subcutaneously every 12 weeks for a total treatment period of 24 weeks.
What makes Upstream Bio’s verekitug unique in clinical development?
Verekitug is described as the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP).
How can investors access Upstream Bio’s VIBRANT trial results webcast?
Investors can access the live webcast through a direct link or via the Events tab in the Investors section
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/8440.html
